Of note, the combination of the CSC‐DC vaccine and dual blockade of programmed death‐ligand 1(PD1) and cytotoxic T‐lymphocyte‐associated protein (CTLA‐4), in murine models of melanoma, Zheng et al112 Proved that triple combination therapy not only could promote the expansion of T‐cell responses against CSCs and inhibit the release of TGF‐β, but it was also more beneficial in the elimination of ALDH CSCs. The gene discussed is CTLA4; the disease is melanoma.